NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Adamas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
In January 2018, Adamas completed a secondary public offering (“SPO”), issuing approximately 3 million shares of common stock priced at $41.50 per share. In October 2018, Merrill Lynch released a study which cast serious doubt on the ability of Gocovri, Adamas’s treatment for dyskinesia in Parkinson’s disease patients treated with levodopa therapy, to achieve a sizeable market share and emphasized that Adamas had failed to include critical information. In March 2019, Adamas backtracked on prior issued growth estimates and no longer made predictions regarding Gocovri’s ability to achieve a sizeable market share. Adamas’s stock price has fallen sharply since the SPO and now trades well below the offering price.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby